Knowledge graph · Drug

Pacritinib

small molecule

Identifier: CI-DRUG-00000446
Entity page: /drug/pacritinib ↗
Edges: 91

Neighbours: 38 cancers4 genes10 trials1 approvals
Drawn: 53 of 53 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pacritinib approved for …APPROVED_FORderived1 of 1
→ approved for	FDA · US · 2022VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L ( 1 ). This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). FDA (US) · approved · 2022-02-28 · VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essentia…	—	approved	not mapped	1

Pacritinib targets …TARGETS4 of 4
→ targets	ACVR1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	IRAK1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FLT3	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	JAK2	—	INHIBITOR	—	1	Curated	chembl	graph →

Pacritinib targets …TARGETS4 of 4

→ targets

ACVR1

—

INHIBITOR

—

Curated

Pacritinib investigated for …INVESTIGATED_FOR15 of 15
→ investigated for	Polycythemia Verahematologic_malignancy	unknown	4	Polycythemia Vera	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Primary Myelofibrosishematologic_malignancy	unknown	4	Primary Myelofibrosis	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	2	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Colorectal Neoplasmsubtype	unknown	2	Colorectal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Myeloproliferative Neoplasmhematologic_malignancy	unknown	2	Myeloproliferative Neoplasm	1	Curated	chembl	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	2	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Hodgkin Lymphomahematologic_malignancy	unknown	2	Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	2	Acute Myeloid Leukemia	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	2	Leukemia	1	Curated	chembl	graph →
→ investigated for	Chronic Myelomonocytic Leukemiahematologic_malignancy	unknown	1	Chronic Myelomonocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Myelodysplastic Syndromehematologic_malignancy	unknown	1	Myelodysplastic Syndrome	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	1	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	1	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	1	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →

Pacritinib investigated in trials for …INVESTIGATED_IN_TRIALSderived35 of 35show fewer
→ investigated in trials for	Primary Myelofibrosishematologic_malignancy 8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Myelofibrosis	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myelomonocytic Leukemiahematologic_malignancy 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myelomonocytic Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic Syndromehematologic_malignancy 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloproliferative Neoplasmhematologic_malignancy 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloproliferative Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Essential Thrombocythemia 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Essential Thrombocythemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemiacancer_family 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Polycythemia Verahematologic_malignancy 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Polycythemia Vera	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Hodgkin Lymphomahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hodgkin Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Indolent Non-Hodgkin Lymphoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Indolent Non-Hodgkin Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoplasmacytic Lymphoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoplasmacytic Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Waldenstrom Macroglobulinemia 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Waldenstrom Macroglobulinemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Accelerated Phase Myeloproliferative Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Accelerated Phase Myeloproliferative Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemia Post Cytotoxic Therapy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia Post Cytotoxic Therapy	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Myeloid Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Atypical Chronic Myeloid Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Atypical Chronic Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Malignant Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Blast Phase Myeloproliferative Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Blast Phase Myeloproliferative Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Juvenile Myelomonocytic Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Juvenile Myelomonocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic/Myeloproliferative Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic/Myeloproliferative Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic Syndrome, Unclassifiable 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome, Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Secondary Acute Myeloid Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Secondary Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	T-Cell and NK-Cell Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	T-Cell and NK-Cell Neoplasm	1	Observed	clinicaltrials	graph →

Pacritinib studied in …STUDIED_INderived10 of 36show all (up to 200)
→ studied in	NCT06303193Phase 1/Phase 2 · recruiting Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms · 36 trials list this drug (16 active)	—	—	Myelodysplastic Syndrome	1	Observed	clinicaltrials	graph →
→ studied in	NCT04282187Phase 2 · recruiting Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms · 36 trials list this drug (16 active)	—	—	Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm,Myeloproliferative Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06782373Phase 2 · active not recruiting A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · 36 trials list this drug (16 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07226713Phase 2 · recruiting Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors · 36 trials list this drug (16 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06052618Phase 2 · recruiting Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) · 36 trials list this drug (16 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07148947Phase 2 · recruiting Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms · 36 trials list this drug (16 active)	—	—	Accelerated Phase Myeloproliferative Neoplasm,Blast Phase Myeloproliferative Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07033598Phase 2 · recruiting Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia · 36 trials list this drug (16 active)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07387354Phase 1/Phase 2 · withdrawn Pacritinib With Aza for Upfront Myelodysplastic Syndrome · 36 trials list this drug (16 active)	—	—	Myelodysplastic Syndrome,Myelodysplastic Syndrome, Unclassifiable,Myeloproliferative Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06159491Phase 1/Phase 2 · recruiting Pacritinib in CMML · 36 trials list this drug (16 active)	—	—	Chronic Myelomonocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06675123Phase 1 · recruiting Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma · 36 trials list this drug (16 active)	—	—	Mantle Cell Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths